318 related articles for article (PubMed ID: 17130680)
1. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis.
Okubo K; Ogino S; Nagakura T; Ishikawa T
Allergol Int; 2006 Dec; 55(4):379-86. PubMed ID: 17130680
[TBL] [Abstract][Full Text] [Related]
2. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated.
Ogino S; Nagakura T; Okubo K; Sato N; Takahashi M; Ishikawa T
Int Arch Allergy Immunol; 2009; 149(3):239-45. PubMed ID: 19218816
[TBL] [Abstract][Full Text] [Related]
3. Anti-IgE antibody therapy for Japanese cedar pollinosis: omalizumab update.
Okubo K; Nagakura T
Allergol Int; 2008 Sep; 57(3):205-9. PubMed ID: 18724074
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis.
Nagakura T; Ogino S; Okubo K; Sato N; Takahashi M; Ishikawa T
Clin Exp Allergy; 2008 Feb; 38(2):329-37. PubMed ID: 18070163
[TBL] [Abstract][Full Text] [Related]
5. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
[TBL] [Abstract][Full Text] [Related]
6. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.
Adelroth E; Rak S; Haahtela T; Aasand G; Rosenhall L; Zetterstrom O; Byrne A; Champain K; Thirlwell J; Cioppa GD; Sandström T
J Allergy Clin Immunol; 2000 Aug; 106(2):253-9. PubMed ID: 10932067
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
Nayak A; Casale T; Miller SD; Condemi J; McAlary M; Fowler-Taylor A; Della Cioppa G; Gupta N
Allergy Asthma Proc; 2003; 24(5):323-9. PubMed ID: 14619332
[TBL] [Abstract][Full Text] [Related]
8. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Chervinsky P; Casale T; Townley R; Tripathy I; Hedgecock S; Fowler-Taylor A; Shen H; Fox H
Ann Allergy Asthma Immunol; 2003 Aug; 91(2):160-7. PubMed ID: 12952110
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
Kuehr J; Brauburger J; Zielen S; Schauer U; Kamin W; Von Berg A; Leupold W; Bergmann KC; Rolinck-Werninghaus C; Gräve M; Hultsch T; Wahn U
J Allergy Clin Immunol; 2002 Feb; 109(2):274-80. PubMed ID: 11842297
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of fluticasone furoate 110 microg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen.
Jacobs R; Martin B; Hampel F; Toler W; Ellsworth A; Philpot E
Curr Med Res Opin; 2009 Jun; 25(6):1393-401. PubMed ID: 19419338
[TBL] [Abstract][Full Text] [Related]
12. Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis.
Casale TB
Am J Respir Crit Care Med; 2001 Oct; 164(8 Pt 2):S18-21. PubMed ID: 11704613
[TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis.
Okubo K; Gotoh M; Fujieda S; Okano M; Yoshida H; Morikawa H; Masuyama K; Okamoto Y; Kobayashi M
Allergol Int; 2008 Sep; 57(3):265-75. PubMed ID: 18566549
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis.
Okamoto Y; Okubo K; Yonekura S; Hashiguchi K; Goto M; Otsuka T; Murata T; Nakao Y; Kanazawa C; Nagakura H; Okawa T; Nakano K; Hisamitsu M; Kaneko S; Konno A
Int Arch Allergy Immunol; 2015; 166(3):177-88. PubMed ID: 25895909
[TBL] [Abstract][Full Text] [Related]
15. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of early treatment of seasonal allergic rhinitis with benifuuki green tea containing O-methylated catechin before pollen exposure: an open randomized study.
Maeda-Yamamoto M; Ema K; Monobe M; Shibuichi I; Shinoda Y; Yamamoto T; Fujisawa T
Allergol Int; 2009 Sep; 58(3):437-44. PubMed ID: 19542766
[TBL] [Abstract][Full Text] [Related]
17. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
19. Preventative effect of a flavonoid, enzymatically modified isoquercitrin on ocular symptoms of Japanese cedar pollinosis.
Hirano T; Kawai M; Arimitsu J; Ogawa M; Kuwahara Y; Hagihara K; Shima Y; Narazaki M; Ogata A; Koyanagi M; Kai T; Shimizu R; Moriwaki M; Suzuki Y; Ogino S; Kawase I; Tanaka T
Allergol Int; 2009 Sep; 58(3):373-82. PubMed ID: 19454839
[TBL] [Abstract][Full Text] [Related]
20. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
